In a strategic push to expand its footprint within the country, healthcare technology startup Qure.ai is intensifying its focus on forging partnerships with central and state governments across India. The company aims to deploy its artificial intelligence (AI) powered diagnostic tools for large-scale health screenings, targeting critical diseases like tuberculosis (TB) and lung cancer.
Shifting Focus to the Public Health Sector
The decision to prioritize government contracts comes as the adoption of AI within India's private healthcare market continues to progress at a slower pace. Currently, India contributes to less than 5% of Qure.ai's total global revenue. However, the company's founder and CEO, Prashant Warier, identifies a massive, untapped opportunity within the public health system.
This potential is starkly highlighted by the nation's disproportionate burden of tuberculosis. According to the World Health Organization's (WHO) Global Tuberculosis Report 2025, India accounted for a staggering 25% of all TB cases worldwide in 2024. The majority of this challenge is concentrated within public health facilities.
"If you look at TB, it is the public sector government hospitals that have TB and one-fourth of the world's TB cases. So, we said, 'Why shouldn't we solve the TB problem in India?'" Warier stated in an interview, underscoring the company's renewed mission.
Early Successes and Future Roadmap
Qure.ai has already made significant inroads by securing key collaborations at both the national and state levels. The company is currently working with prestigious bodies like the Indian Council of Medical Research (ICMR) and the central government on various TB screening initiatives.
At the state level, the startup has successfully inked partnerships with Goa, Karnataka, and Jammu and Kashmir for TB and lung cancer screening programs. In a more recent development, Qure.ai began providing its AI-driven stroke screening tool to the Punjab government for use in select district hospitals.
Warier believes that cracking the government market is the key to achieving exponential growth in India. While Qure.ai's technology is present in approximately 4,500 hospitals globally, only about 5-10% of these are located in India. The company plans to add up to 3,000 hospitals worldwide this year, and Warier anticipates a "disproportionate number" of these new additions could come from India. "Suddenly one deployment, you deploy across 500 hospitals," he noted, highlighting the scalability of government projects.
The PPP Model and Global Revenue Streams
To facilitate this expansion, Qure.ai is actively utilizing the Public-Private Partnership (PPP) model. This approach provides a solid foundation for AI firms to integrate their technology into the existing public health infrastructure. Warier confirmed that the company plans to engage either directly with governments or partner with companies already involved in PPPs. It is not alone in this strategy; other health AI firms like Niramai Health Analytix are also pursuing collaborations with state governments.
While India represents a major future growth avenue, Qure.ai's current revenue engine is powered by international markets. The United States contributes about one-third of its overall revenue, followed by Europe at 10-15%. The remainder comes from various low- and middle-income countries. Warier attributes the smaller commercial opportunity in India's private sector to its limited size and lower capacity to pay for advanced AI solutions compared to well-insured markets like the US.
Financially, the company saw its operating revenue grow by 24.5% to ₹175.5 crore in the fiscal year 2025. However, rising costs led to a widening of losses by 87.5%, which stood at ₹90 crore. Backed by a total funding of $121 million from investors such as Peak XV Partners, HealthQuad, and Novo Holdings, Qure.ai was valued at $264 million in its last funding round in November 2024. Despite the current losses, Warier is optimistic, expecting the company to turn profitable within the next couple of years as its global and Indian public-sector initiatives gain significant momentum.
